Author

C. Criscitiello

Observed name: C Criscitiello

Institutions: University of Milan, European Institute of Oncology

Observed institutions: Shanghai Jiao Tong University, University of Milan, Shanghai Chest Hospital, European Institute of Oncology

OpenAlex ID: A5052093602

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival

2026 · Y. Wang, D. Drubay, et al. · Annals of Oncology · 1

226P Prevalence and characteristics of HR+/HER2- MBC with ESR1 mutations post-CDK inhibitor therapy

2024 · R. Scafetta, K. Venetis, et al. · ESMO Open

90P Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials

2023 · J. Uliano, E. Nicolo, et al. · ESMO Open

83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population

2022 · L. Mazzarella, E. Nicolo, et al. · Immuno-Oncology Technology

乳癌における腫瘍浸潤リンパ球(til)の評価国際til作業グループ2014年による推奨

2015 · R Salgado, C Denkert, et al. · Annals of Oncology

Works count: 5

Citation count: 1

H-index: 1

I10-index: